Floatz logo

Zilovertamab

Lymphoproliferative Disorders

Oncternal Therapeutics, Incmonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

27 Active assets in the Lymphoproliferative Disorders cohort.

Asset / SponsorPhaseRating
Darbepoetin Alfa
Mayo Clinic
Phase 3BB
Epoetin Alfa
Mayo Clinic
Phase 3BB
Fludarabine
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 2BB
Baclofen
Alliance for Clinical Trials in Oncology
Phase 3BB
Tabelecleucel
Pierre Fabre Medicament
Phase 3BB

View all 50 →

Same molecule, other indications

Zilovertamab is also rated in:

mantle cell lymphomaDormant
BB
Indicative ·
64 / 100
View asset →
lymphatic system disorderDormant
B
Indicative ·
60 / 100
View asset →
immunoproliferative disorderDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →